Login to Your Account

Companies Forge Ahead

PRC Awaiting U.S./EU/WHO Biosimilars Guidance

By Cornelia Zou
Contributing Writer

Wednesday, October 23, 2013

HONG KONG – Defying all expectations of an early announcement, biosimilar developers in China are unlikely to see any kind of regulatory framework in the near future.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription